John Magenau, MD, on Alpha-1-Antitrypsin for High-Risk Acute GVHD

February 24, 2025 By The ASCO Post Staff

John Magenau, MD, of the University of Michigan, presents results from the phase III BMT CTN 1705 trial, which explored the efficacy of alpha-1-antitrypsin (AAT) plus corticosteroids vs corticosteroids alone for the treatment of high-risk acute graft-vs-host disease (GVHD) following allogeneic hematopoietic stem cell transplant.

Related Content